# Claritev Corporation (CTEV)

> Source: Nexqual · https://nexqual.com/CTEV · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Claritev Corporation (CTEV), nexqual.com/CTEV" · informational, not investment advice.

**Price:** USD 23.86 (-0.33% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 23.94 · day 23.07–24.14 · 52w 11.5–73.68 · market cap $404M · NYQ

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $995M, net income -$283M (-28.5% margin), free cash flow -$17.9M (SEC filings).
- Analysts: Buy (mean 1.80 on a 1–5 scale) (5 analysts), mean target USD 46 (range 30–73).
- Total return with dividends: 1Y -57.8% vs S&P 500 +18.1%; 5Y -87.1% vs S&P 500 +85.1%.
- Next earnings: 2026-11-09, EPS estimate USD 1.71, revenue estimate $256M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $1.12B | $1.08B | $962M | $931M | $965M | $995M |
| Operating income | $386M | -$363M | $162M | -$1.39B | $28.8M | $32.5M |
| Net income | $102M | -$573M | -$91.7M | -$1.65B | -$284M | -$283M |
| EPS (diluted) | $6.40 | -$36.00 | -$5.69 | -$101.92 | -$17.30 | — |
| Free cash flow | $320M | $283M | $62.9M | -$10.5M | -$12.3M | -$17.9M |
| Operating margin | 34.5% | -33.6% | 16.8% | -149.4% | 3.0% | 3.3% |
| Net margin | 9.1% | -53.1% | -9.5% | -176.9% | -29.4% | -28.5% |
| Revenue growth | +19.2% | -3.4% | -10.9% | -3.2% | +3.7% | — |
| Cash + short-term investments | $185M | $334M | $71.5M | $16.8M | $16.8M | — |
| Total debt | $4.99B | $4.84B | $4.61B | $4.58B | $4.63B | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/S 0.4x · EV/EBITDA 37.5x · EV/Sales 5.1x · FCF yield -4.43% · Earnings yield -70.01% · Net debt $4.64B · EV $5.04B

## Analysts
Consensus Buy (mean 1.80 on a 1–5 scale), 5 analysts; mean target USD 46 (low 30, high 73).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-21 | Barclays | Target raised | Overweight | $28 → $40 |
| 2026-08-12 | Wells Fargo | Target raised | Equal-Weight | $22 → $30 |
| 2026-08-10 | Citigroup | Target raised | Buy | $40 → $45 |
| 2026-08-10 | Canaccord Genuity | Target raised | Buy | $37 → $43 |
| 2026-07-21 | Canaccord Genuity | Target raised | Buy | $32 → $37 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -57.8% | -87.1% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -57.9% | -33.6% |
| Volatility (annualized) | 127.9% | 115.4% |
| Max drawdown | -81.1% (Oct 2025→Feb 2026) | -97.4% (Jun 2022→Dec 2024) |

## Peers (Health Information Services)
CARL (Carlsmed, Inc.) USD 13.95 -3.59% · NRC (NRC Health) USD 21.11 +4.66% · EVH (Evolent Health, Inc) USD 4.87 +5.87% · SOPH (SOPHiA GENETICS SA) USD 7.29 +2.82% · WEAV (Weave Communications, Inc.) USD 7.39 +0.27% · PHR (Phreesia, Inc.) USD 11.04 +2.70%

## More
Full page: https://nexqual.com/CTEV · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt